Want to see SE:BIOEX full AI Analyst Report?
Top Page
Bioextrax AB
(BIOEX)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr2.50
▼(-21.63% Downside)
Action:Reiterated
Date:08/21/26
The score is pressured primarily by weak financial performance—persistent losses, declining recent revenue, and ongoing negative cash flow with higher cash burn—despite the benefit of having no debt. Technical indicators also point to a weak trend (price below key moving averages, negative MACD, low RSI), while valuation is difficult to support using a negative P/E and lacks dividend yield data.
Positive Factors
Debt-Free Balance Sheet
A debt-free capital structure limits refinancing and interest-rate risk, giving Bioextrax greater flexibility to fund research, partnerships, and commercialization without servicing a significant debt burden.
Negative Factors
Declining Revenue Scale
Small and declining revenue limits commercial proof, customer concentration resilience, and the ability to absorb fixed research and operating costs. Continued contraction would make it harder to reach efficient production scale and support self-funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A debt-free capital structure limits refinancing and interest-rate risk, giving Bioextrax greater flexibility to fund research, partnerships, and commercialization without servicing a significant debt burden.
Read all positive factors
Bioextrax AB (BIOEX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr111.39M
Dividend YieldN/A
Average Volume (3M)94.92K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-37.50%
EPS Growth0.99%
CountrySE
Employees14
SectorIndustrials
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding47,601,730
10 Day Avg. Volume101,209
30 Day Avg. Volume94,920
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.23
Price to Sales (P/S)146.53
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)kr1.73M
Bioextrax AB Business Overview & Revenue Model
Company Description
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granu...
How the Company Makes Money
Bioextrax AB makes money primarily by commercializing fermentation-produced bio-based ingredients and related know-how. Key revenue streams include: (1) Sales of products/ingredients: revenue from supplying its bio-based materials (e.g., biopolyme...
Bioextrax AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 360.00K | 757.00K | 515.00K | 2.06M | 395.00K | 275.76K |
| Gross Profit | -14.84M | -16.43M | -915.00K | 718.00K | -18.64M | -11.29M |
| EBITDA | -14.16M | -17.24M | -16.18M | -20.65M | -18.19M | -10.18M |
| Net Income | -14.24M | -17.70M | -17.34M | -21.51M | -18.67M | -10.53M |
Balance Sheet | ||||||
| Total Assets | 14.49M | 24.73M | 29.00M | 22.52M | 37.92M | 12.64M |
| Cash, Cash Equivalents and Short-Term Investments | 7.39M | 3.93M | 17.27M | 13.40M | 27.53M | 8.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.51M | 3.51M | 2.94M | 1.98M | 6.15M | 5.14M |
| Stockholders Equity | 11.98M | 21.21M | 26.06M | 20.54M | 31.77M | 7.50M |
Cash Flow | ||||||
| Free Cash Flow | -23.61M | -26.20M | -18.99M | -24.41M | -24.38M | -9.45M |
| Operating Cash Flow | -23.34M | -26.05M | -18.78M | -23.31M | -17.60M | -8.48M |
| Investing Cash Flow | -277.00K | -152.00K | -215.00K | -1.10M | -6.78M | -975.13K |
| Financing Cash Flow | 12.58M | 12.86M | 22.86M | 10.28M | 42.94M | 16.38M |
Bioextrax AB Technical Analysis
Negative
3.19
Price Trends
2.49
Negative
2.52
Negative
2.48
Negative
Market Momentum
-0.04
Negative
48.26
Neutral
76.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Negative. The current price of 3.19 is above the 20-day moving average (MA) of 2.35, above the 50-day MA of 2.49, and above the 200-day MA of 2.48, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 48.26 is Neutral, neither overbought nor oversold. The STOCH value of 76.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOEX.
Bioextrax AB Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
53 Neutral | kr122.16M | -1.17 | -81.76% | ― | 55.24% | 70.00% | |
48 Neutral | kr139.03M | -2.71 | -81.23% | ― | -4.02% | 35.86% | |
48 Neutral | kr89.82M | -2.42 | -106.23% | ― | -97.37% | 25.28% | |
48 Neutral | kr115.52M | -2.78 | ― | ― | ― | 13.53% | |
41 Neutral | kr111.39M | -5.44 | -116.56% | ― | -37.50% | 0.99% | |
41 Neutral | kr137.80M | -2.68 | 245.07% | ― | -38.46% | 9.02% |
* Industrials Sector Average
SE:BIOEX
Bioextrax AB
2.36
-0.92
-28.14%
SE:XINT
Xintela AB
0.16
-0.22
-58.68%
SE:BIOVIC.B
Biovica International AB Class B
0.42
-0.21
-32.96%
SE:NXTCL
NextCell Pharma AB
1.04
-0.07
-6.31%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.06
-34.86%
SE:ANNX
Annexin Pharmaceuticals AB
13.00
-14.58
-52.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.